See more : Pidilite Industries Limited (PIDILITIND.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Aeglea BioTherapeutics, Inc. (AGLE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aeglea BioTherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Maschinenfabrik Heid AG (HED.VI) Income Statement Analysis – Financial Results
- B+S Banksysteme Aktiengesellschaft (DTD2.DE) Income Statement Analysis – Financial Results
- Sanco Industries Limited (SANCO.NS) Income Statement Analysis – Financial Results
- Vulcan Steel Limited (VSL.AX) Income Statement Analysis – Financial Results
- China Petroleum & Chemical Corporation (SNPTY) Income Statement Analysis – Financial Results
Aeglea BioTherapeutics, Inc. (AGLE)
About Aeglea BioTherapeutics, Inc.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 58.58M | 57.07M | 59.64M | 64.60M | 36.72M | 22.82M | 18.14M | 11.45M | 6.83M |
| General & Administrative | 28.53M | 27.32M | 21.84M | 15.73M | 12.63M | 10.07M | 8.39M | 5.95M | 2.07M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.53M | 27.32M | 21.84M | 15.73M | 12.63M | 10.07M | 8.39M | 5.95M | 2.07M |
| Other Expenses | -7.00K | -122.00K | -5.00K | -63.00K | -57.00K | -42.00K | -36.00K | -2.00K | 0.00 |
| Operating Expenses | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Cost & Expenses | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Interest Income | 837.00K | 111.00K | 593.00K | 2.14M | 1.17M | 482.00K | 244.00K | 22.00K | 1.00K |
| Interest Expense | 837.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.57M | 1.58M | 996.00K | 418.00K | 293.00K | 249.00K | 132.00K | 89.00K | 19.00K |
| EBITDA | -84.78M | -65.65M | -80.49M | -80.33M | -44.06M | -27.68M | -21.77M | -11.23M | -7.44M |
| EBITDA Ratio | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,133.10% | -531.72% | -470.48% | -184.49% | 0.00% |
| Operating Income | -84.78M | -65.65M | -81.48M | -80.33M | -45.46M | -27.68M | -21.91M | -11.32M | -8.90M |
| Operating Income Ratio | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,169.32% | -531.72% | -473.34% | -185.95% | 0.00% |
| Total Other Income/Expenses | 830.00K | -11.00K | 588.00K | 2.08M | -57.00K | -42.00K | -36.00K | 20.00K | -1.44M |
| Income Before Tax | -83.95M | -65.66M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Income Before Tax Ratio | -3,604.59% | -350.39% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| Income Tax Expense | -136.00K | 141.00K | -593.00K | -2.56M | -57.00K | -731.00K | -244.00K | -22.00K | 1.44M |
| Net Income | -83.82M | -65.80M | -80.30M | -75.69M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Net Income Ratio | -3,598.75% | -351.14% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| EPS | -24.86 | -25.02 | -37.61 | -59.23 | -53.25 | -45.01 | -55.40 | -24.71 | -37.93 |
| EPS Diluted | -24.86 | -25.02 | -37.61 | -59.23 | -53.25 | -45.01 | -55.40 | -24.71 | -37.93 |
| Weighted Avg Shares Out | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 272.80K |
| Weighted Avg Shares Out (Dil) | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 272.80K |
Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency
AUSTIN, Texas, May 3, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it has completed patient randomization for...
Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021
AUSTIN, Texas, April 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced it will participate in two virtual investor conferences in...
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
AUSTIN, Texas, March 18, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today reported its fourth quarter and full year 2020 financial results,...
Aeglea (AGLE) Upgraded to Buy: Here's Why
Aeglea (AGLE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aeglea BioTherapeutics Appoints Alison Lawton to Board of Directors
AUSTIN, Texas, Dec. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the appointment of...
Aeglea BioTherapeutics Receives FDA Rare Pediatric Disease Designation for ACN00177 for the Treatment of Homocystinuria
AUSTIN, Texas, Dec. 1, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high burden diseases, today announced the U.S. Food and...
Aeglea BioTherapeutics to Participate in Two Upcoming Virtual Investor Conferences
AUSTIN, Texas, Nov. 17, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced it will participate in...
Steven Cohen Jumps Back Into Aeglea BioTherapeutics
Billionaire investor Steven Cohen (Trades, Portfolio) revealed a new stake in Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) late last week.
Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria
AUSTIN, Texas, Oct. 26, 2020 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare and other high-burden diseases, today announced the U.S. Food and Drug...
Aeglea Bio Therapeutics (NASDAQ:AGLE) Downgraded by BidaskClub to “Sell”
Aeglea Bio Therapeutics (NASDAQ:AGLE) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, BidAskClub reports. Other equities analysts also recently issued research reports about the...
Source: https://incomestatements.info
Category: Stock Reports